SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Sanofi – ‘6-K’ for 5/3/18

On:  Thursday, 5/3/18, at 9:23am ET   ·   For:  5/3/18   ·   Accession #:  1193125-18-149764   ·   File #:  1-31368

Previous ‘6-K’:  ‘6-K’ on / for 4/27/18   ·   Next:  ‘6-K’ on / for 5/22/18   ·   Latest:  ‘6-K’ on / for 3/20/24

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 5/03/18  Sanofi                            6-K         5/03/18    3:77K                                    Donnelley … Solutions/FA

Current Report by a Foreign Private Issuer   —   Form 6-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current Report by a Foreign Private Issuer          HTML     12K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     17K 
 3: EX-99.2     Miscellaneous Exhibit                               HTML     19K 


6-K   —   Current Report by a Foreign Private Issuer


This is an HTML Document rendered as filed.  [ Alternative Formats ]



  6-K  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of May 2018

Commission File Number: 001-31368

 

 

SANOFI

(Translation of registrant’s name into English)

 

 

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes   ☐             No  ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-                

 

 

 


In May 2018, Sanofi issued the press releases attached hereto as Exhibit 99.1 and 99.2 which are incorporated herein by reference.

Exhibit List

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated May 2, 2018: Annual General Shareholders’ Meeting of May 2, 2018
Exhibit 99.2
   Press release dated April 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

 

2


Exhibit Index

 

Exhibit No.

  

Description

Exhibit 99.1    Press release dated May 2, 2018: Annual General Shareholders’ Meeting of May 2, 2018
Exhibit 99.2    Press release dated April 30, 2018: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

 

3


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: May 3, 2018

            SANOFI
      By  

    /s/ Alexandra Roger

        Name:   Alexandra Roger
       

Title:

 

Head of Securities Law and Capital Markets

 

4


Dates Referenced Herein

This ‘6-K’ Filing    Date    Other Filings
Filed on / For Period End:5/3/18None on these Dates
5/2/18
4/30/18
 List all Filings 
Top
Filing Submission 0001193125-18-149764   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Mar. 29, 5:56:24.1am ET